Dissecting the IL‐6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R

AIMS: Chronic inflammation is a risk factor for cardiovascular disease (CVD). IL‐6 signalling perturbation through IL‐6 or IL‐6R blockade may have potential benefit on cardiovascular risk. It is unknown whether targeting either IL‐6 or IL‐6 receptor may result in similar effects on CVD and adverse e...

Descripción completa

Detalles Bibliográficos
Autores principales: Cupido, Arjen J., Asselbergs, Folkert W., Natarajan, Pradeep, Ridker, Paul M., Hovingh, G. Kees, Schmidt, A. Floriaan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303316/
https://www.ncbi.nlm.nih.gov/pubmed/34931349
http://dx.doi.org/10.1111/bcp.15191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303316/
https://www.ncbi.nlm.nih.gov/pubmed/34931349
http://dx.doi.org/10.1111/bcp.15191

Ejemplares similares